Hydrochlorothiazide-induced hyperuricaemia in the pharmacogenomic evaluation of antihypertensive responses study

Journal of Internal Medicine

Volumn 276, Issue 5, 2014, Pages 486-497

  Vandell, A G ^a   Mcdonough, C W ^a   Gong, Y ^a   Langaee, T Y ^a   Lucas, A M ^a   Chapman, A B ^b   Gums, J G ^a,c   Beitelshees, A L ^d   Bailey, K R ^e   Johnson, R J ^f   Boerwinkle, E ^g   Turner, S T ^e   Cooper Dehoff, R M ^a,c   Johnson, J A ^a,c  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Genome wide association study; Hydrochlorothiazide; Hypertension; Pharmacogenetics; Polymorphism; Uric acid

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; HYDROCHLOROTHIAZIDE; MICRORNA; THIAZIDE DIURETIC AGENT; URIC ACID; DIURETIC AGENT;

ADD ON THERAPY; AFRICAN AMERICAN; ALLELE; ANKRD17 GENE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; COX18 GENE; DRUG DOSE TITRATION; DRUG MECHANISM; FEMALE; FTO GENE; GENE; GENE EXPRESSION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HYDROCHLOROTHIAZIDE INDUCED HYPERURICEMIA; HYPERTENSION; HYPERURICEMIA; LUC7L2 GENE; MALE; MONOTHERAPY; PADI4 GENE; PARD3B GENE; PHARMACOGENOMICS; PHENOTYPE; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; ADULT; BLOOD; CHEMICALLY INDUCED; GENETIC ASSOCIATION; GENETICS; MIDDLE AGED; PHARMACOGENETICS; RISK FACTOR;

ADULT; AFRICAN AMERICANS; ANTIHYPERTENSIVE AGENTS; DIURETICS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; HYPERURICEMIA; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84911394024     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12215     Document Type: Article

References (43)

1. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011; 63: 3136-3141.
2. Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007; 49: 298-303.
3. Mellen PB, Bleyer AJ, Erlinger TP et al. Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension 2006; 48: 1037-1042.
4. Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford) 2008; 47: 1567-1570.
5. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991; 266: 3008-3011.
6. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003; 42: 474-480.
7. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007; 120: 442-447.
8. Tuttle KR, Short RA, Johnson RJ. Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol 2001; 87: 1411-1414.
9. Mazzali M, Hughes J, Kim YG et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101-1106.
10. Nakagawa T, Hu H, Zharikov S et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006; 290: F625-F631.
11. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300: 924-932.
12. Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleosides, Nucleotides Nucleic Acids 2008; 27: 608-619.
13. Sica DA. Diuretic-related side effects: development and treatment. J Clin Hypertens (Greenwich) 2004; 6: 532-540.
14. Drugs Topic Staff. 2010 Top 200 generic drugs by total prescriptions. Drug Topics 2011; drugtopics.modernmedicine.com.
15. Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol 2003; 18: 523-530.
16. Reungjui S, Roncal CA, Mu W et al. Thiazide diuretics exacerbate fructose-induced metabolic syndrome. J Am Soc Nephrol 2007; 18: 2724-2731.
17. Steele TH, Oppenheimer S. Factors affecting urate excretion following diuretic administration in man. Am J Med 1969; 47: 564-574.
18. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4. Br J Pharmacol 2008; 155: 1066-1075.
19. Hagos Y, Stein D, Ugele B, Burckhardt G, Bahn A. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol 2007; 18: 430-439.
20. Emmerson BT, Nagel SL, Duffy DL, Martin NG. Genetic control of the renal clearance of urate: a study of twins. Ann Rheum Dis 1992; 51: 375-377.
21. Wilk JB, Djousse L, Borecki I et al. Segregation analysis of serum uric acid in the NHLBI Family Heart Study. Hum Genet 2000; 106: 355-359.
22. Vitart V, Rudan I, Hayward C et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008; 40: 437-442.
23. Dehghan A, Kottgen A, Yang Q et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 2008; 372: 1953-1961.
24. Kolz M, Johnson T, Sanna S et al. Meta-analysis of 28, 141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 2009; 5: e1000504.
25. Fan AZ, Yesupriya A, Chang MH et al. Gene polymorphisms in association with emerging cardiovascular risk markers in adult women. BMC Med Genet 2010; 11: 6.
26. Johnson JA, Boerwinkle E, Zineh I et al. Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J 2009; 157: 442-449.
27. Purcell S, Neale B, Todd-Brown K et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
28. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-909.
29. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 2010; 26: 2190-2191.
30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
31. Howell VM, Jones JM, Bergren SK et al. Evidence for a direct role of the disease modifier SCNM1 in splicing. Hum Mol Genet 2007; 16: 2506-2516.
32. Sacconi S, Trevisson E, Pistollato F et al. hCOX18 and hCOX19: two human genes involved in cytochrome c oxidase assembly. Biochem Biophys Res Commun 2005; 337: 832-839.
33. Gerken T, Girard CA, Tung YC et al. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science 2007; 318: 1469-1472.
34. Frayling TM, Timpson NJ, Weedon MN et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007; 316: 889-894.
35. Scott LJ, Mohlke KL, Bonnycastle LL et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007; 316: 1341-1345.
36. Guo Y, Liu H, Yang TL et al. The fat mass and obesity associated gene, FTO, is also associated with osteoporosis phenotypes. PLoS ONE 2011; 6: e27312.
37. Watt AJ, Jones EA, Ure JM, Peddie D, Wilson DI, Forrester LM. A gene trap integration provides an early in situ marker for hepatic specification of the foregut endoderm. Mech Dev 2001; 100: 205-215.
38. Hou SC, Chan LW, Chou YC et al. Ankrd17, an ubiquitously expressed ankyrin factor, is essential for the vascular integrity during embryogenesis. FEBS Lett 2009; 583: 2765-2771.
39. Deng M, Li F, Ballif BA et al. Identification and functional analysis of a novel cyclin e/cdk2 substrate ankrd17. J Biol Chem 2009; 284: 7875-7888.
40. Tanikawa C, Espinosa M, Suzuki A et al. Regulation of histone modification and chromatin structure by the p53-PADI4 pathway. Nat Commun 2012; 3: 676.
41. Hou S, Gao GP, Zhang XJ et al. PADI4 polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis. Mod Rheumatol 2013; 23: 50-60.
42. Izaki T, Kamakura S, Kohjima M, Sumimoto H. Phosphorylation-dependent binding of 14-3-3 to Par3beta, a human Par3-related cell polarity protein. Biochem Biophys Res Commun 2005; 329: 211-218.
43. Below JE, Gamazon ER, Morrison JV et al. Genome-wide association and meta-analysis in populations from Starr County, Texas, and Mexico City identify type 2 diabetes susceptibility loci and enrichment for expression quantitative trait loci in top signals. Diabetologia 2011; 54: 2047-2055.